ArticleAnimal models and experimental medicine2026
Mechanistic investigation of Liujing Toutong tablet in the treatment of cerebral ischemia-reperfusion injury in rats by the integration of serum pharmacochemistry and metabolomics.
Article in Animal models and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundLiujing Toutong tablet (LTT) is a traditional Chinese patent medicine. Previous studies have demonstrated that LTT exerts a protective effect in permanent cerebral ischemia and cerebral ischemia-reperfusion injury (CIRI). However, the active compounds and underlying mechanisms remain unclear. This investigation aimed to integrate the analyses of serum pharmacochemistry, network pharmacology, and metabolomics to elucidate the therapeutic effects of LTT on CIRI.
methodsThe therapeutic effects of LTT were evaluated in the CIRI rat model, which was induced using the thread embolism method. The prototype active compounds of LTT absorbed into the serum (LPCs) were identified using ultra-performance liquid chromatography-quadrupole/orbitrap high-resolution mass spectrometry (UPLC-Q-Exactive-Orbitrap/MS). Potential targets of LPCs were determined using network pharmacological analysis. A combination of metabolomics and network pharmacology was employed to identify upstream key targets and downstream endogenous metabolites. The predicted mechanisms were then verified by molecular docking. Finally, key targets and signaling pathways were examined using enzyme-linked immunosorbent assay (ELISA) and Western blot.
resultsA total of 27 LPCs were identified as the active ingredients. Furthermore, glycerophospholipid and arachidonic acid (AA) metabolism were also identified, with PTGS2, ALOX5, and AchE as the upstream key targets, and phosphorylcholine, AA, phosphatidate (PA), hosphatidylcholines (PCs), and lysophosphatidylcholines (LysoPCs) as the core endogenous metabolites. Additionally, LPCs binding with these key targets might reduce the inflammatory response via nuclear factor Kappa-B (NF-κB) signaling pathway.
conclusionLTT may effectively alleviate symptoms of CIRI by acting on PTGS2, ALOX5, and AchE, improving the glycerophospholipid and AA metabolism and reducing the inflammatory response by inhibiting NF-κB signaling pathway-related proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.